COVID-19 Blog
KOL Collaborators Present Microbix HPV Test-Control Results
announces that it is presenting results of a novel Quality Assessment Product (“QAP™”) for supporting patient diagnosis and tissue analysis relating to infection with the Herpes Simplex Virus (“HSV”) at the European Meeting on Molecular Diagnostics (“EMMD”) taking place in Noordwijk, The Netherlands, October 9 to 11, 2024.
Microbix Presents Novel HSV Test Control at EMMD
announces that it is presenting results of a novel Quality Assessment Product (“QAP™”) for supporting patient diagnosis and tissue analysis relating to infection with the Herpes Simplex Virus (“HSV”) at the European Meeting on Molecular Diagnostics (“EMMD”) taking place in Noordwijk, The Netherlands, October 9 to 11, 2024.
Microbix Achieves Essential EU Regulatory Accreditations
Microbix announces that it has upgraded its European Union (“EU”) regulatory compliance for its diagnostic assay quality assessment products (“QAPs™”).
Microbix’s Corporate Presentation
Profitable growth from supporting next generation Diagnostics. Click below to download..
Microbix Presenting at Muskoka Capital Conference
Microbix will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 27 to 29, 2024.
Microbix Reports Continued Strong Results for Q3 Fiscal 2024
Microbix Biosystems Inc. reports results for its third quarter and first nine months of fiscal 2024 ended June 30, 2024 (“Q3” and “YTD”) with strong revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and resulting in material net income for Q3 and YTD.
Microbix Schedules Release of Results for Q3 Fiscal 2024
Microbix Biosystems Inc. announces that it expects to file the financial statements and management disclosure and analysis for its third quarter of fiscal 2024 ended June 30, 2024 (“Q3 2024”) prior to the start of trading on August 14, 2024.
Microbix Presents HCV FLOQSwab® Format Test Control at ADLM
Microbix Biosystems Inc. introduces a novel Quality Assessment Product (QAP™) for Hepatitis C Virus (HCV) POCTs at the ADLM conference. This swab-based, room-temperature stable control aims to enhance accessibility and accuracy of HCV testing, especially in low-resource settings.
Microbix Hosts Minister Nina Tangri to Open Capacity Expansions
Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces its hosting of Associate Minister of Small Business of Ontario, the Honourable Nina Tangri, to celebrate the opening of two expansions to its medical devices manufacturing capacity at one of its three adjacent Mississauga sites.
Microbix Advances Test-Ingredient Manufacturing Capabilities
Microbix is a global leader in the production of native Antigens – preparations of purified and inactivated bacteria and viruses essential for the manufacture of “immunoassays.”